Nutrien maintains strong outlook with strategic shifts despite slight EPS miss, CIBC keeps 'Outperform' rating.

Nutrien reported strong Q2 financials with $2.40 billion adjusted EBITDA and $10.81 billion revenue, though EPS of $2.61 missed estimates. CIBC kept an 'Outperform' rating but lowered the price target slightly to $84 from $85. The company raised its 2026 potash sales forecast and plans to cut capital spending while increasing share buybacks, signaling confidence in growth and shareholder value enhancement. These moves reflect Nutrien's proactive strategy amid evolving market conditions.